Research graph
References from Oxidative lipoprotein remodelling in atherogenesis: Mechanistic insights and therapeutic potential. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
The impact of unhealthy lifestyle on the burden of non-communicable diseases in the State of Qatar: a systematic analysis of the global burden of disease study 2021
10.1177/15598276251405214 · 2025 · External reference
Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis
10.1016/s2214-109x(18)30275-4 · 2018 · External reference
Determinants of dyslipidemia in Africa: a systematic review and meta-analysis
10.3389/fcvm.2021.778891 · 2022 · External reference
Cardiovascular diseases in Africa in the twenty-first century: gaps and priorities going forward
10.3389/fcvm.2022.1008335 · 2022 · External reference
Hypertension in low- and middle-income countries
10.1161/circresaha.120.318729 · 2021 · External reference
Hypertension in sub-Saharan Africa: the current profile, recent advances, gaps, and priorities
2025 · External reference
African regional and national burden of diabetes mellitus and its attributable risk factors from 1990 to 2021: results from the global burden of disease study 2021
2025 · External reference
Impact of dyslipidemia in the development of cardiovascular complications: delineating the potential therapeutic role of coenzyme Q(10)
10.1016/j.biochi.2022.08.018 · 2023 · External reference
Oxidative stress and its role in vascular damage and atherosclerosis
10.3390/ijms27021075 · 2026 · External reference
Oxidative stress, atherogenic dyslipidemia, and cardiovascular risk
10.3390/biomedicines11112897 · 2023 · External reference
Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis
10.1186/s41043-025-01054-3 · 2025 · External reference
Awareness, treatment, and control of dyslipidemia in rural South Africa: the HAALSI (Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa) study
10.1371/journal.pone.0187347 · 2017 · External reference
Dyslipidaemia in South Africa
10.7196/samj.2018.v108i4.13265 · 2018 · External reference
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia
10.3389/fcvm.2024.1389106 · 2024 · External reference
LDL biochemical modifications: a link between atherosclerosis and aging
10.3402/fnr.v59.29240 · 2015 · External reference
Small dense LDL: an underestimated driver of atherosclerosis (review)
10.3892/mmr.2025.13693 · 2025 · External reference
Endothelial dysfunction in atherosclerosis: experimental models and therapeutics
10.34133/bmr.0252 · 2025 · External reference
The African genome variation project shapes medical genetics in Africa
10.1038/nature13997 · 2015 · External reference
Gender-related differences in the prevalence of cardiovascular disease risk factors and their correlates in urban Tanzania
10.1186/1471-2261-9-30 · 2009 · External reference
Oxidized low-density lipoproteins and their contribution to atherosclerosis
2025 · External reference
Dysregulation of the low-density lipoprotein receptor pathway is involved in lipid disorder-mediated organ injury
10.7150/ijbs.14027 · 2016 · External reference
The role of oxidative stress in atherosclerosis
10.3390/cells11233843 · 2022 · External reference
Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events
10.2217/bmm.11.60 · 2011 · External reference
Oxidized LDL triggers changes in oxidative stress and inflammatory biomarkers in human macrophages
10.1016/j.redox.2017.11.017 · 2018 · External reference
Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME study
10.1016/s0021-9150(03)00280-6 · 2003 · External reference
Antioxidant-enzyme interaction in non-communicable diseases
10.14218/jerp.2024.00020 · 2024 · External reference
Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system
10.1161/circresaha.111.243972 · 2012 · External reference
Cardiovascular disease risk factors are associated with conventional lipids and apolipoproteins in South African adults of African ancestry
10.1186/s12944-025-02591-w · 2025 · External reference
Triglycerides, triglyceride-rich lipoproteins, and remnant cholesterol in atherosclerotic cardiovascular disease
10.12997/jla.2025.14.3.247 · 2025 · External reference
Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia
10.1161/atvbaha.111.241463 · 2012 · External reference
Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis
10.3389/fcvm.2022.925923 · 2022 · External reference
Oxidized LDLs as signaling molecules
2021 · External reference
Remnant lipoproteins: are they equal to or more atherogenic than LDL?
10.1097/mol.0000000000000682 · 2020 · External reference
Recognition of oxidized lipids by macrophages and its role in atherosclerosis development
10.3390/biomedicines9080915 · 2021 · External reference
Immunity and inflammation in atherosclerosis
10.1161/circresaha.118.313591 · 2019 · External reference
Anti-oxidized LDL antibodies and coronary artery disease: a systematic review
2019 · External reference
Role of the adaptive immune system in atherosclerosis
10.1042/bst20200602 · 2020 · External reference
Oxidized phospholipid oxPAPC induces a Th1-like phenotype in regulatory T cells and inhibits their protective function in atherosclerosis
10.1161/atvbaha.123.319674 · 2023 · External reference
Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis – novel insights and future directions in diagnosis and therapy
10.1016/j.tcm.2018.05.010 · 2019 · External reference
Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women?
10.1016/j.jacc.2006.03.057 · 2006 · External reference
Analytical validation of monoclonal antibody-based ELISA methods for OxPL-apoB and OxPL-apo(a)
10.1016/j.jlr.2026.100976 · 2026 · External reference
Determination of oxidized phosphatidylcholines by hydrophilic interaction liquid chromatography coupled to Fourier transform mass spectrometry
10.3390/ijms16048351 · 2015 · External reference
Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL
10.1373/clinchem.2005.064337 · 2006 · External reference
Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease
10.1161/01.cir.98.15.1487 · 1998 · External reference
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease
10.1161/01.atv.21.5.844 · 2001 · External reference
Oxidized low-density lipoprotein associates with cardiovascular disease by a vicious cycle of atherosclerosis and inflammation: a systematic review and meta-analysis
10.3389/fcvm.2022.1023651 · 2023 · External reference
OxLDL as a prognostic biomarker of plaque instability in patients qualified for carotid endarterectomy
10.1111/jcmm.18459 · 2024 · External reference
Serum OxLDL levels are positively associated with the number of ischemic events and damaged blood vessels in patients with coronary artery disease
10.3390/healthcare13121426 · 2025 · External reference
LDL oxidation and cerebrovascular aging: mechanisms of endothelial dysfunction, inflammation, and vascular cognitive impairment and dementia
10.1016/j.redox.2026.104118 · 2026 · External reference
Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus
10.4239/wjd.v6.i3.456 · 2015 · External reference
The effect of bariatric surgery on circulating levels of oxidized low-density lipoproteins is apparently independent of changes in body mass index: a systematic review and meta-analysis
10.1155/2021/4136071 · 2021 · External reference
Oxidative stress is progressively enhanced with advancing stages of CKD
10.1053/j.ajkd.2006.08.015 · 2006 · External reference
Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides
10.1080/00325481.2019.1643633 · 2019 · External reference
Genetic factors contributing to atherosclerosis
10.1097/hco.0000000000001286 · 2026 · External reference
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
10.1097/mol.0000000000000114 · 2014 · External reference
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
10.1038/ng1161 · 2003 · External reference
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
10.1038/ng1509 · 2005 · External reference
PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor
10.1038/s41467-024-46336-2 · 2024 · External reference
APOE gene variants in primary dyslipidemia
10.1016/j.atherosclerosis.2021.05.007 · 2021 · External reference
PCSK9 loss-of-function variants, low-density lipoprotein cholesterol, and risk of coronary heart disease and stroke: data from 9 studies of blacks and whites
10.1161/circgenetics.116.001632 · 2017 · External reference
Molecular population genetics of PCSK9: a signature of recent positive selection
10.1097/fpc.0b013e3282f44d99 · 2008 · External reference
High frequency of the apolipoprotein E *4 allele in African pygmies and most of the African populations in sub-Saharan Africa
1997 · External reference
Apolipoprotein E genotypes and their relation to lipid levels in a rural South African population 1
10.1080/14034950701355635 · 2007 · External reference
LDL-cholesterol-lowering effects of a dietary supplement containing onion and garlic extract used in healthy volunteers
10.3390/nu16162811 · 2024 · External reference
Regulatory efficacy of fermented plant extract on the intestinal microflora and lipid profile in mildly hypercholesterolemic individuals
10.1016/j.jfda.2016.10.008 · 2017 · External reference
10.1161/circulationaha.122.059410
10.1161/circulationaha.122.059410 · 2022 · External reference
Probucol in albuminuric type 2 diabetes mellitus patients on renin-angiotensin system blockade: a 16-week, randomized, double-blind, placebo-controlled trial
10.1161/atvbaha.116.308034 · 2016 · External reference
Weight loss achieved by bariatric surgery modifies high-density lipoprotein subfractions and low-density lipoprotein oxidation towards atheroprotection
10.1016/j.clinbiochem.2018.10.007 · 2019 · External reference
An adapted cardioprotective diet with or without phytosterol and/or krill oil supplementation in familial hypercholesterolemia: results of a pilot randomized clinical trial
10.3390/nu17122008 · 2025 · External reference
Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia
10.1194/jlr.p068585 · 2016 · External reference
Additional consumption of one egg per day increases serum lutein plus zeaxanthin concentration and lowers oxidized low-density lipoprotein in moderately hypercholesterolemic males
10.1016/j.foodres.2017.03.003 · 2017 · External reference
Lipid oxidation products and the risk of cardiovascular diseases: role of lipoprotein transport
2024 · External reference
A practical guide to the management of dyslipidaemia
10.1007/s00392-025-02833-y · 2026 · External reference
Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the International Lipid Expert Panel (ILEP)
10.1016/j.phrs.2021.105499 · 2021 · External reference
A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9
10.1002/clc.22687 · 2017 · External reference
Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers
10.1186/s12944-018-0909-z · 2018 · External reference
Effects of Probucol on plasma amyloid-beta transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial
10.1186/s12944-024-02398-1 · 2024 · External reference
Therapeutic strategies targeting oxidative stress and inflammation: a narrative review
10.3390/biochem5040035 · 2025 · External reference
Effects of Icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR study)
10.1016/j.amjcard.2019.05.057 · 2019 · External reference
Oxidative stress in the pathophysiology of kidney disease: implications for noninvasive monitoring and identification of biomarkers
10.1155/2020/5478708 · 2020 · External reference
Long-term comparison of ethyl Icosapentate vs. omega-3-acid ethyl in patients with cardiovascular disease and hypertriglyceridemia (DEFAT trial)
10.1253/circj.cj-18-0764 · 2019 · External reference
Oxidative stress and inflammation: what polyphenols can do for us?
10.1155/2016/7432797 · 2016 · External reference
Bioactivity of dietary polyphenols: the role in LDL-C lowering
10.3390/foods10112666 · 2021 · External reference
The cholesterol-lowering effect of unripe Rubus coreanus is associated with decreased oxidized LDL and apolipoprotein B levels in subjects with borderline-high cholesterol levels: a randomized controlled trial
10.1186/s12944-020-01338-z · 2020 · External reference
“Benifuuki” extract reduces serum levels of lectin-like oxidized low-density lipoprotein receptor-1 ligands containing apolipoprotein B: a double-blind placebo-controlled randomized trial
10.3390/nu10070924 · 2018 · External reference
Chios mastiha essential oil exhibits antihypertensive, hypolipidemic and anti-obesity effects in metabolically unhealthy adults - a randomized controlled trial
10.1016/j.phrs.2023.106821 · 2023 · External reference
Polyphenols, inflammation, and cardiovascular disease
10.1007/s11883-013-0324-x · 2013 · External reference
Ubiquinol ameliorates endothelial dysfunction in subjects with mild-to-moderate dyslipidemia: a randomized clinical trial
10.3390/nu12041098 · 2020 · External reference
Coenzyme Q10 supplementation improves cholesterol efflux capacity and antiinflammatory properties of high-density lipoprotein in Chinese adults with dyslipidemia
10.1016/j.nut.2022.111703 · 2022 · External reference
Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations
10.1016/j.mito.2007.03.003 · 2007 · External reference
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
10.1056/nejmoa1001689 · 2011 · External reference
The role of NADPH oxidases in the etiology of obesity and metabolic syndrome: contribution of individual isoforms and cell biology
10.1089/ars.2018.7674 · 2019 · External reference
The effects of a novel nutraceutical combination on low-density lipoprotein cholesterol and other markers of cardiometabolic health in adults with hypercholesterolaemia: a randomised double-blind placebo-controlled trial
10.1016/j.atherosclerosis.2025.119177 · 2025 · External reference
Various apolipoprotein E genotypes relate to responsiveness to flaxseed lignan complex in older persons with type 2 diabetes mellitus
10.2478/enr-2024-0026 · 2024 · External reference
Variability in the beneficial effects of phenolic compounds: a review
10.3390/nu14091925 · 2022 · External reference
Carotenoid enrichment in eggs: from biochemistry perspective
10.1016/j.aninu.2023.05.012 · 2023 · External reference
Effect of short-term hazelnut consumption on DNA damage and oxidized LDL in children and adolescents with primary hyperlipidemia: a randomized controlled trial
10.1016/j.jnutbio.2018.03.012 · 2018 · External reference
Clinoptilolite for treatment of dyslipidemia: preliminary efficacy study
10.1089/acm.2016.0414 · 2017 · External reference
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
10.1016/s0140-6736(23)00215-5 · 2023 · External reference
Atherogenic lipoproteins for the statin residual cardiovascular disease risk
10.3390/ijms232113499 · 2022 · External reference
Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins
10.3389/fcvm.2023.1308173 · 2024 · External reference
Pleiotropic effects of statins on the cardiovascular system
10.1161/circresaha.116.308537 · 2017 · External reference
Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
10.1194/jlr.m003566 · 2010 · External reference
Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 EQUATOR study)
10.1016/j.amjcard.2017.02.020 · 2017 · External reference
Ezetimibe therapy: mechanism of action and clinical update
2012 · External reference
Adding ezetimibe to statin therapy: latest evidence and clinical implications
10.7573/dic.212534 · 2018 · External reference
Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential
10.1080/13543784.2020.1778668 · 2020 · External reference
Cholesterol lowering drugs
2000 · External reference
Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: a state-of-the-art review
10.1002/phar.4635 · 2025 · External reference
PCSK9 inhibitors: the evolving future
10.1002/hsr2.70174 · 2024 · External reference
Oxidized high-density lipoprotein is associated with increased plasma glucose in non-diabetic dyslipidemic subjects
10.1016/j.cca.2012.08.021 · 2012 · External reference
Abstract 4139206: design of Heart-2: a phase 1b clinical trial of VERVE-102, an in vivo base editing medicine delivered by a GalNAc-LNP and targeting PCSK9 to durably lower LDL cholesterol
10.1161/circ.150.suppl_1.4139206 · 2024 · External reference
Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management
10.1186/s12872-026-05515-3 · 2026 · External reference
HDL cholesterol efflux capacity and incident cardiovascular events
10.1056/nejmoa1409065 · 2014 · External reference
Pharmacogenomics: the genetics of variable drug responses
10.1161/circulationaha.109.914820 · 2011 · External reference
The lipoprotein(a) implementation gap: bridging evidence and clinical practice
10.31083/rcm47152 · 2026 · External reference
Lipoprotein(a) and ethnicities
10.1016/j.atherosclerosis.2022.04.005 · 2022 · External reference
Lp(a)-associated oxidized phospholipids in healthy black and white participants in relation to apo(a) size, age, and family structure
10.1161/jaha.120.020158 · 2021 · External reference
Current clinical trials for treating elevated lipoprotein(a)
10.1007/s12170-025-00759-8 · 2025 · External reference
Treatment of Lp(a): is it the future or are we ready today?
10.1007/s11883-023-01141-y · 2023 · External reference
Lipoprotein(a) in the year 2024: a look back and a look ahead
10.1161/atvbaha.124.319483 · 2024 · External reference
